N-Methyl-D-aspartate (NMDA) receptors are ligand- and voltage-gated ion channels essential for synaptic plasticity, learning, and memory. The GluN2B subunit, highly expressed in the forebrain and spinal cord, is implicated in multiple neurological and psychiatric disorders, making it an attractive target for positron emission tomography (PET) imaging. However, the development of selective GluN2B PET radioligands remains challenging. Here, we describe the design, synthesis, and evaluation of eighteen 3-alkylaryl derivatives of 7-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol, including enantiomerically resolved compounds, as candidate PET radioligands. Structure–activity relationship studies show that binding affinity is largely insensitive to electronic and steric variation at the terminal aryl group but strongly dependent on alkyl linker length, with a four-carbon chain providing optimal affinity. Binding affinity does not correlate with calculated lipophilicity, suggesting hydrophobicity is not the primary determinant of receptor interaction. Absolute configuration was established using vibrational circular dichroism and infrared spectroscopy, and docking studies provided insight into enantiomer-specific binding modes. Two ligands, L3 and L6, and their enantiomers exhibited high GluN2B affinity, favorable physicochemical properties, and suitability for carbon-11 labeling. Separate PET imaging studies confirmed strong and specific brain binding of the radiolabeled compounds. These findings establish this scaffold as a promising platform for GluN2B PET ligand development.
N-Methyl-D-aspartate (NMDA) receptors are ligand- and voltage-gated ion channels essential for synaptic plasticity, learning, and memory. The GluN2B subunit, highly expressed in the forebrain and spinal cord, is implicated in multiple neurological and psychiatric disorders, making it an attractive target for positron emission tomography (PET) imaging. However, the development of selective GluN2B PET radioligands remains challenging. Here, we describe the design, synthesis, and evaluation of eighteen 3-alkylaryl derivatives of 7-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol, including enantiomerically resolved compounds, as candidate PET radioligands. Structure–activity relationship studies show that binding affinity is largely insensitive to electronic and steric variation at the terminal aryl group but strongly dependent on alkyl linker length, with a four-carbon chain providing optimal affinity. Binding affinity does not correlate with calculated lipophilicity, suggesting hydrophobicity is not the primary determinant of receptor interaction. Absolute configuration was established using vibrational circular dichroism and infrared spectroscopy, and docking studies provided insight into enantiomer-specific binding modes. Two ligands, L3 and L6, and their enantiomers exhibited high GluN2B affinity, favorable physicochemical properties, and suitability for carbon-11 labeling. PET imaging confirmed strong and specific brain binding of the radiolabeled compounds. These findings establish this scaffold as a promising platform for GluN2B PET ligand development.
Background: GluN2B-subunits of N-methyl-D-aspartate (NMDA) receptors are therapeutic targets for neuropsychiatric disorders, but an effective positron emission tomography (PET) radioligand for human GluN2B brain imaging is still needed. We developed [11C]MeRo25, a 11C-methylated derivative of the GluN2B-preferring ligand Ro 25-6981 and evaluated its suitability as a GluN2B PET radioligand. Methods: MeRo25 was synthe-sized by methylation of Ro 25-6981, and affinities for GluN2B and σ1 receptors were de-termined in vitro. [11C]MeRo25 was prepared using [11C]methyl iodide. PET studies were performed in rats and monkeys at baseline and after challenge with GluN2B or σ1 recep-tor-directed ligands. In monkeys, regional total distribution volume (VT) was estimated by kinetic modeling. Results: MeRo25 showed low nanomolar affinity for GluN2B and σ1 re-ceptors. [11C]MeRo25 was obtained in 20–30% radiochemical yield, > 99% purity, and high molar activity. [11C]MeRo25 showed rapid and high brain uptake in rats and monkeys. Pretreatment with either GluN2B or σ1 receptor-directed ligands in monkey markedly re-duced brain radioactivity and regional VT, demonstrating contributions from both receptor populations. Conclusions: Despite favorable brain uptake and high GluN2B affinity, [11C]MeRo25 exhibits substantial σ1 receptor binding, producing a mixed GluN2B/σ1 re-ceptor PET signal that precludes its use as a selective GluN2B radioligand. These findings emphasize the importance of in vivo pharmacological validation and reveal limitations of the Ro 25-6981 scaffold for selective GluN2B PET radioligand development. This study also cautions against the use of Ro 25-6981 as a pharmacological tool where binding to s1 receptors may be of concern, for example as a challenge agent in PET studies.
Fluorine‐18 is an attractive positron‐emitter for positron emission tomography (PET) because of its half‐life ( t1/2 = 109.8 min) and availability as [ 18 F]fluoride ion in high activity from biomedical cyclotrons. For 18 F‐labeled tracers intended to image low‐density protein targets (e.g., receptors, transporters and enzymes), the molar activity ( Am ) must be high (usually > 37 GBq μmol −1 ) to comply with the tracer principle, avoid attenuation of specific signal, and minimize pharmacological effects. Typically, Am is determined by measuring radioactivity with an ionization chamber and total tracer isotopologue mass with high‐performance liquid chromatography with ultraviolet absorbance detection. Molar activities often vary widely across day‐to‐day tracer productions and between PET radiochemistry laboratories. The terminal radiometric methods provide little insight into sources of carrier. Here, we describe accurate and simple nonradiometric methods for measuring Am for [ 18 F]fluoride through highly sensitive liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) on two rapidly derived surrogates, [ 18 F]fallypride and [ 18 F]4‐(pyrrolidine‐1‐carbonyl)benzenesulfonyl fluoride. These methods can serve as forensic tools for investigating the sources of carrier in tracer syntheses and for Am determinations during routine tracer productions. Moreover, the LC‐MS/MS technique can be applied to radiotracers lacking a strong UV chromophore, as with [ 18 F]2‐fluoro‐2‐deoxy‐D‐glucose tetraacetate, an intermediate in the synthesis of the most widely used PET tracer, [ 18 F]2‐fluoro‐2‐deoxy‐D‐glucose.
Background/Objectives: GluN2B subunits of N-methyl-D-aspartate (NMDA) receptors are therapeutic targets for neuropsychiatric disorders, but an effective positron emission tomography (PET) radioligand for human GluN2B brain imaging is still needed. We developed [11C]MeRo25, a 11C-methylated derivative of the GluN2B-preferring ligand Ro 25-6981, and evaluated its suitability as a GluN2B PET radioligand. Methods: MeRo25 was synthesized through methylation of Ro 25-6981, and affinities for GluN2B and σ1 receptors were determined in vitro. [11C]MeRo25 was prepared using [11C]methyl iodide. PET studies were performed in rats and monkeys at baseline and after challenge with GluN2B or σ1 receptor-directed ligands. In monkeys, regional total distribution volume (VT) was estimated through kinetic modeling. Results: MeRo25 showed low nanomolar affinity for GluN2B and σ1 receptors. [11C]MeRo25 was obtained with a radiochemical yield of 20–30%, a purity of >99%, and high molar activity. [11C]MeRo25 showed rapid and high brain uptake in rats and monkeys. Pretreatment with either GluN2B or σ1 receptor-directed ligands in monkeys markedly reduced brain radioactivity and regional VT, demonstrating contributions from both receptor populations. Conclusions: Despite favorable brain uptake and high GluN2B affinity, [11C]MeRo25 exhibits substantial σ1 receptor binding, producing a mixed GluN2B/σ1 receptor PET signal that precludes its use as a selective GluN2B radioligand. These findings emphasize the importance of in vivo pharmacological validation and reveal limitations of the Ro 25-6981 scaffold for selective GluN2B PET radioligand development. This study also cautions against the use of Ro 25-6981 as a pharmacological tool where binding to σ1 receptors may be of concern, for example as a challenge agent in PET studies.